圣诺生物(688117.SH)：2025年度净利润1.66亿元，同比增长231.49%

Core Viewpoint - Shengnuo Biotech (688117.SH) reported significant growth in its 2025 annual performance, driven by the increasing demand for peptide drugs in the global market, particularly in the areas of glucose reduction and weight loss [1] Financial Performance - The company achieved an operating revenue of 741 million yuan, representing a year-on-year increase of 62.55% [1] - The net profit attributable to the parent company reached 166 million yuan, marking a substantial year-on-year growth of 231.49% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 173 million yuan, reflecting a remarkable year-on-year increase of 278.52% [1] Business Focus - During the reporting period, the company maintained a strong focus on the synergistic development of its core businesses, including peptide drug CDMO, active pharmaceutical ingredients, and formulations [1] - The significant increase in sales of GLP-1 active pharmaceutical ingredients contributed to the substantial improvement in operational performance [1]